{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RPRX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T13:07:51.085Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1924,"canonical_name":"Royalty Pharma plc","cik":"0001802768","uei":null,"lei":null,"duns":null,"ticker":"RPRX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":74},"count":74,"timeline":[{"ts":"2026-10-05","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-10-05","url_slug":"/sec/cik-0001802768/144/0001964306-26-000465","accession_number":"0001964306-26-000465","importance":30},{"ts":"2026-10-05","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-10-05","url_slug":"/sec/cik-0001802768/4/0001838139-26-000028","accession_number":"0001838139-26-000028","importance":30},{"ts":"2026-09-30","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-09-30","url_slug":"/sec/cik-0001802768/4/0001838139-26-000026","accession_number":"0001838139-26-000026","importance":30},{"ts":"2026-09-28","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-09-28","url_slug":"/sec/cik-0001802768/144/0001964306-26-000456","accession_number":"0001964306-26-000456","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-09-24","url_slug":"/sec/cik-0001802768/4/0001814238-26-000017","accession_number":"0001814238-26-000017","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-09-22","url_slug":"/sec/cik-0001802768/144/0001628280-26-063061","accession_number":"0001628280-26-063061","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-08-19","url_slug":"/sec/cik-0001802768/4/0001814238-26-000015","accession_number":"0001814238-26-000015","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-08-18","url_slug":"/sec/cik-0001802768/144/0001628280-26-057721","accession_number":"0001628280-26-057721","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-08-17","url_slug":"/sec/cik-0001802768/4/0001814876-26-000027","accession_number":"0001814876-26-000027","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"13F-NT","title":"13F-NT — Royalty Pharma plc — 2026-08-14","url_slug":"/sec/cik-0001802768/13f-nt/0001802768-26-000018","accession_number":"0001802768-26-000018","importance":30},{"ts":"2026-08-13","kind":"sec.insider.s","reporter":"Coyne Terrance P.","title":"EVP & CFO","shares":9230,"price_per_share":58.5864,"usd_value":540752,"security_title":"Class A Ordinary Shares","importance":35.540752472},{"ts":"2026-08-13","kind":"sec.insider.s","reporter":"Coyne Terrance P.","title":"EVP & CFO","shares":1772,"price_per_share":59.1415,"usd_value":104799,"security_title":"Class A Ordinary Shares","importance":35.104798738},{"ts":"2026-08-13","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-08-13","url_slug":"/sec/cik-0001802768/144/0001958244-26-000508","accession_number":"0001958244-26-000508","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-08-07","url_slug":"/sec/cik-0001802768/4/0001814238-26-000013","accession_number":"0001814238-26-000013","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-08-07","url_slug":"/sec/cik-0001802768/4/0001814876-26-000025","accession_number":"0001814876-26-000025","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-08-07","url_slug":"/sec/cik-0001802768/4/0001838139-26-000024","accession_number":"0001838139-26-000024","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Royalty Pharma plc — 2026-08-05","url_slug":"/sec/cik-0001802768/10-q/0001802768-26-000015","accession_number":"0001802768-26-000015","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Royalty Pharma plc — 2026-08-05","url_slug":"/sec/cik-0001802768/8-k/0001802768-26-000014","accession_number":"0001802768-26-000014","importance":35},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Legorreta Pablo G.","title":"CEO, Chairman of the Board","shares":65216,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Coyne Terrance P.","title":"EVP & CFO","shares":11002,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":11002,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":8252,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-07-02","url_slug":"/sec/cik-0001802768/4/0001814238-26-000011","accession_number":"0001814238-26-000011","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-07-02","url_slug":"/sec/cik-0001802768/4/0001838139-26-000022","accession_number":"0001838139-26-000022","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"SCH Investment Partners LLC","title":"Officer","shares":100000,"usd_value":5709000,"security_title":"Class A Ordinary Shares","approx_sale_date":"2026-06-30","accession_number":"0001628280-26-046352","importance":41.1418},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Urist Marshall","title":"Officer","shares":9099,"usd_value":508454,"security_title":"Common Stock","approx_sale_date":"2026-07-01","accession_number":"0001964306-26-000306","importance":40.101690764},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":9099,"price_per_share":55.8802,"usd_value":508454,"security_title":"Class A Ordinary Shares","importance":35.5084539398},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-07-01","url_slug":"/sec/cik-0001802768/144/0001628280-26-046352","accession_number":"0001628280-26-046352","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-07-01","url_slug":"/sec/cik-0001802768/144/0001964306-26-000306","accession_number":"0001964306-26-000306","importance":30},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":97446,"price_per_share":56.5028,"usd_value":5505972,"security_title":"Class A Ordinary Shares","importance":40.5059718488},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":29400,"price_per_share":56.4423,"usd_value":1659404,"security_title":"Class A Ordinary Shares","importance":36.65940362},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":2554,"price_per_share":57.1031,"usd_value":145841,"security_title":"Class A Ordinary Shares","importance":35.1458413174},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":600,"price_per_share":57.09,"usd_value":34254,"security_title":"Class A Ordinary Shares","importance":35.034254},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Bassler Bonnie L","title":"","shares":689,"price_per_share":54.3998,"usd_value":37481,"security_title":"Class A Ordinary Shares","importance":15.0374814622},{"ts":"2026-06-25","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-06-25","url_slug":"/sec/cik-0001802768/4/0001814238-26-000009","accession_number":"0001814238-26-000009","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-06-25","url_slug":"/sec/cik-0001802768/4/0001838139-26-000020","accession_number":"0001838139-26-000020","importance":30},{"ts":"2026-06-24","kind":"sec.form144","reporter":"Urist Marshall","title":"Officer","shares":9098,"usd_value":502067,"security_title":"Common Stock","approx_sale_date":"2026-06-24","accession_number":"0001964306-26-000296","importance":40.10041331},{"ts":"2026-06-24","kind":"sec.insider.s","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":9098,"price_per_share":55.1843,"usd_value":502067,"security_title":"Class A Ordinary Shares","importance":35.5020667614},{"ts":"2026-06-24","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-06-24","url_slug":"/sec/cik-0001802768/144/0001964306-26-000296","accession_number":"0001964306-26-000296","importance":30},{"ts":"2026-06-23","kind":"sec.form144","reporter":"SCH Investment Partners LLC","title":"Officer","shares":150000,"usd_value":8166766,"security_title":"Class A Ordinary Shares","approx_sale_date":"2026-06-23","accession_number":"0001628280-26-044947","importance":41.633353226},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":117592,"price_per_share":54.4746,"usd_value":6405777,"security_title":"Class A Ordinary Shares","importance":41.4057771632},{"ts":"2026-06-23","kind":"sec.form144","reporter":"Christopher Hite","title":"Officer","shares":30000,"usd_value":1660500,"security_title":"Class A Ordinary Shares","approx_sale_date":"2026-06-23","accession_number":"0001628280-26-044949","importance":40.3321},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Hite Christopher","title":"EVP & Chairman, Partnering","shares":32408,"price_per_share":54.107,"usd_value":1753500,"security_title":"Class A Ordinary Shares","importance":36.753499656},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-06-23","url_slug":"/sec/cik-0001802768/144/0001628280-26-044947","accession_number":"0001628280-26-044947","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-06-23","url_slug":"/sec/cik-0001802768/144/0001628280-26-044949","accession_number":"0001628280-26-044949","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Royalty Pharma plc — 2026-06-16","url_slug":"/sec/cik-0001802768/schedule-13d-a/0001140361-26-025447","accession_number":"0001140361-26-025447","importance":70},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-06-08","url_slug":"/sec/cik-0001802768/4/0001796439-26-000003","accession_number":"0001796439-26-000003","importance":30},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"WEATHERMAN ELIZABETH H","title":null,"shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"LOVE TED W","title":"","shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"HODGSON DAVID C","title":null,"shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Bassler Bonnie L","title":"","shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Coric Vlad","title":null,"shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Ho Carole","title":null,"shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Engelbert Catherine M.","title":"","shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Norden Gregory","title":"","shares":4545,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Royalty Pharma plc — 2026-06-04","url_slug":"/sec/cik-0001802768/8-k/0001193125-26-257432","accession_number":"0001193125-26-257432","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-05-21","url_slug":"/sec/cik-0001802768/4/0001838139-26-000018","accession_number":"0001838139-26-000018","importance":30},{"ts":"2026-05-20","kind":"sec.form144","reporter":"Urist Marshall","title":"Officer","shares":13684,"usd_value":721837,"security_title":"Common Stock","approx_sale_date":"2026-05-20","accession_number":"0001964306-26-000251","importance":40.144367442},{"ts":"2026-05-20","kind":"sec.insider.s","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":13684,"price_per_share":52.7505,"usd_value":721838,"security_title":"Class A Ordinary Shares","importance":35.721837842},{"ts":"2026-05-20","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-05-20","url_slug":"/sec/cik-0001802768/144/0001964306-26-000251","accession_number":"0001964306-26-000251","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-05-15","url_slug":"/sec/cik-0001802768/4/0001838139-26-000016","accession_number":"0001838139-26-000016","importance":30},{"ts":"2026-05-14","kind":"sec.form144","reporter":"Urist Marshall","title":"Officer","shares":13684,"usd_value":726138,"security_title":"Common Stock","approx_sale_date":"2026-05-14","accession_number":"0001964306-26-000239","importance":40.145227564},{"ts":"2026-05-14","kind":"sec.form144","reporter":"Norden Gregory","title":"Officer","shares":3045,"usd_value":161385,"security_title":"Common Stock","approx_sale_date":"2026-05-14","accession_number":"0001964306-26-000240","importance":40.032277},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":13684,"price_per_share":53.0647,"usd_value":726137,"security_title":"Class A Ordinary Shares","importance":35.7261373548},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Norden Gregory","title":"","shares":3045,"price_per_share":53,"usd_value":161385,"security_title":"Class A Ordinary Shares","importance":35.161385},{"ts":"2026-05-14","kind":"sec.filing","form_type":"13F-NT","title":"13F-NT — Royalty Pharma plc — 2026-05-14","url_slug":"/sec/cik-0001802768/13f-nt/0001802768-26-000012","accession_number":"0001802768-26-000012","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"144","title":"144 — Royalty Pharma plc — 2026-05-14","url_slug":"/sec/cik-0001802768/144/0001964306-26-000239","accession_number":"0001964306-26-000239","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-05-08","url_slug":"/sec/cik-0001802768/4/0001814238-26-000007","accession_number":"0001814238-26-000007","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-05-08","url_slug":"/sec/cik-0001802768/4/0001814876-26-000020","accession_number":"0001814876-26-000020","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Royalty Pharma plc — 2026-05-08","url_slug":"/sec/cik-0001802768/4/0001838139-26-000014","accession_number":"0001838139-26-000014","importance":30},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"Legorreta Pablo G.","title":"CEO, Chairman of the Board","shares":143821,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"Hite Christopher","title":"EVP & Vice Chairman","shares":24263,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"Urist Marshall","title":"EVP, Research & Investments","shares":18197,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-06","kind":"sec.insider.a","reporter":"Coyne Terrance P.","title":"EVP & CFO","shares":24263,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15}]}